I agree, the headline came from somewhere. I think it is bogus, which is why I'll add to my postion. Probably a hedgefund wanting to set the tone for starting trading. Could have a short or large put postion. Or wants to accumulate.
I don't see where everyone keeps saying mixed guidance. they raise revenues from 7.5 to 7.6 billion and raised the EPS from 3.50 - 3.60 to 3.60 - 3.65. If you go buy their own guidance that puts them on a path to 7.50 (split adjusted) EPS for 2017, I would say they are clearly beating their own goals. If CELG sells off at all, I will be adding to it. this will be back to $150 by 2017 for another double on top of the last one. This stock just keeps doubling and makes me feel like a genius for buying it.
Seems like forward guidance is not mixed. I very good quarter. I think alot of Analyst's didn't think the growth would come in as it did.
are downplaying. In any case base on the 12 month trajectory, the price targets will be increased. I am a buyer on any weakness. Which if pre-market is an indication, I'll be adding. IMHO a stellar quarter.
CELG beats by a penny and raises guidance by a dime.
There are spending quite a bit on R&D and stock buybacks...
CELG not so much. They raised forward guidance by a dime.
I suspect the stock sells off a bit with this report?
Back to $85?
Role: Lead the development and execution of a Celgene I&I program/compound development/Life Cycle strategy. Responsible for creating the overall program/compound’s development/life Cycle strategy.
Lead program/project team(s) to develop integrated cross-functional program/compound implementation plan based on the governance committee approved development/life cycle strategy. etc on corp website
Often, the analysts' expectations are already priced in the stock. That's why I took profits in my CELG short last Thursday. I haven't gone long at this price and won't until after the quarterly report (if warranted).